Healthcare Industry News:  Micrus Endovascular 

Devices Ophthalmology Personnel

 News Release - February 7, 2011

ReVision Optics Announces the Appointment of John T. Kilcoyne as CEO and President

LAKE FOREST, Calif.--(Healthcare Sales & Marketing Network)-- ReVision Optics, Inc. (RVO) a leading research and development company specializing in implantable microlens technology to treat presbyopia, today announced the appointment of John T. Kilcoyne as Chief Executive Officer and President. Mr. Kilcoyne will succeed J. Randy Alexander. Mr. Alexander will assume the role of Chairman of the Board.

“John’s broad range of experience in the medical device industry and his demonstrated ability to understand the needs of patients and physicians made him the best person for this position,” said Alexander, RVO Chairman. “As RVO moves from our research and development stage into commercialization it’s more important than ever to have someone with John’s background at the helm. We are delighted that he has joined our company.”

Kilcoyne has more than 29 years of experience in the medical device market. Most recently he served as Chairman and CEO of Micrus Endovascular Corporation, until its sale to Johnson & Johnson in September 2010. Kilcoyne also previously served as President and Chief Executive Officer of Solace Therapeutics from 2002 to 2004 and Endonetics from 1997 until its acquisition by Medtronic in December 2001.

“I am honored to join RVO at this pivotal time in their development,” said Kilcoyne. The potential for their technology and the depth of experience of their employees made this the right choice. I believe that RVO’s PresbyLens® technology provides a unique approach to solving the problem of presbyopia.”

The PresbyLens® is a corneal microlens and unique patented refractive surgery solution designed to improve the near and intermediate vision that has been lost due to the eye's natural aging process also known as presbyopia. The miniature lens made of a medical grade "hydrogel" material is similar to the material used in soft contact lenses. During a short surgical procedure, the PresbyLens® is implanted into the front layers of the cornea in order to microscopically change the shape of the eye's surface. The market for this kind of refractive surgery to correct aging eyes is growing exponentially as the baby boomers and millions of others around the world battle presbyopia and search for alternatives to bifocals.

The PresbyLens® has received a CE mark and is approved to be sold in Europe under the name of Vue+TM. RVO is actively pursuing regulatory approvals for the PresbyLens® in the United States.


ReVision Optics™, Inc., (RVO) is a privately held corporation headquartered in Southern California. The company’s main focus is the research and development of custom optical solutions dedicated to vision correction.

RVO’s first product is the PresbyLens®* inlay, a unique patented refractive surgery solution. This inlay is designed to improve the near vision that has been lost by the eye’s natural aging process called presbyopia. The PresbyLens® inlay is removable, and provides an ideally suited surgical option for near and intermediate vision enhancement.

The Company is actively pursuing regulatory approvals and market opportunities for the PresbyLens® worldwide. The PresbyLens® has its CE mark and is approved in Europe under the name of Vue+TM. For more information on PresbyLens or RVO please visit

* Caution, the PresbyLens® is an Investigational Device and is limited by United States federal law to investigational use.

Source: ReVision Optics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.